Delta President Says Overall Revenue Could Rise 10% in Q2 and Corcept Therapeutics Ends Late Stage Trial of Mifepristone
Delta Air Lines Inc. (NYSE: DAL) - announced an important revenue measure that would show gains in May and June. The company said that unit revenue, or passenger revenue per available seat mile, would likely rise in the 6 percent to 7 percent range for both May and June. This is compared with a growth forecast of 5 percent to 7 percent Delta gave last month. Delta President Edward Bastian told a Bank of America Merrill Lynch conference that revenue outlook was "very solid." He noted that Delta's overall revenue could rise 10 percent in the current second quarter.
Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo worldwide. Its route network comprises various gateway airports in Amsterdam, Atlanta, Cincinnati, Detroit, Memphis, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita. The company sells its tickets through various distribution channels, including telephone reservations, delta.com, traditional brick and mortar, and online travel agencies.
Get more information on Delta Air Lines Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/DAL
TrendingWallStreet.com wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. TrendingWallStreet.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get full access to our free stock reports.
Corcept Therapeutics Incorporated (NASDAQ: CORT) ended a late-stage trial of its depression treatment drug Mifepristone because it is unlikely to produce positive results.. Analysis determined it was unlikely to succeed after data analysis from the first 226 patients enrolled in the trial determined the drug did not significantly reduce psychotic depression symptoms. The company plans to focus their attention onto other programs, especially oncology.
Corcept Therapeutics Incorporated, a pharmaceutical company, is engaged in the discovery, development, and commercialization of drugs for the treatment of metabolic, psychiatric, and oncologic disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Get more information on Corcept Therapeutics Incorporated and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/CORT
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.
Tags: